Schneider Capital Management Corp Sells 11,000 Shares of Endo International PLC (ENDP)
Schneider Capital Management Corp reduced its holdings in shares of Endo International PLC (NASDAQ:ENDP) (TSE:ENL) by 1.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 631,311 shares of the company’s stock after selling 11,000 shares during the period. Endo International PLC accounts for about 1.3% of Schneider Capital Management Corp’s investment portfolio, making the stock its 26th largest holding. Schneider Capital Management Corp owned about 0.28% of Endo International PLC worth $7,052,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. James Investment Research Inc. purchased a new position in Endo International PLC during the 2nd quarter valued at about $113,000. Blair William & Co. IL purchased a new position in Endo International PLC during the 2nd quarter valued at about $126,000. Point View Wealth Management Inc. lifted its position in Endo International PLC by 16.6% during the 2nd quarter. Point View Wealth Management Inc. now owns 13,331 shares of the company’s stock valued at $149,000 after acquiring an additional 1,900 shares during the period. Riverhead Capital Management LLC lifted its position in Endo International PLC by 64.4% during the 2nd quarter. Riverhead Capital Management LLC now owns 15,025 shares of the company’s stock valued at $168,000 after acquiring an additional 5,887 shares during the period. Finally, Bank of Hawaii purchased a new position in Endo International PLC during the 2nd quarter valued at about $180,000. 90.71% of the stock is owned by institutional investors.
In related news, CEO Paul Campanelli acquired 6,500 shares of the firm’s stock in a transaction that occurred on Monday, August 14th. The stock was purchased at an average cost of $7.71 per share, with a total value of $50,115.00. Following the transaction, the chief executive officer now directly owns 213,620 shares of the company’s stock, valued at approximately $1,647,010.20. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Terrance J. Coughlin acquired 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 10th. The stock was bought at an average cost of $7.70 per share, with a total value of $154,000.00. Following the completion of the transaction, the chief operating officer now directly owns 181,369 shares in the company, valued at $1,396,541.30. The disclosure for this purchase can be found here. Insiders purchased a total of 36,000 shares of company stock valued at $279,460 over the last ninety days. 0.50% of the stock is currently owned by insiders.
Shares of Endo International PLC (NASDAQ ENDP) traded down 7.171% during mid-day trading on Thursday, hitting $8.336. 5,235,430 shares of the stock were exchanged. Endo International PLC has a 52-week low of $7.41 and a 52-week high of $21.87. The stock has a 50-day moving average price of $8.70 and a 200 day moving average price of $10.59. The firm’s market cap is $1.86 billion.
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings data on Tuesday, August 8th. The company reported $0.93 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.19. The firm had revenue of $875.73 million during the quarter, compared to analyst estimates of $832.66 million. Endo International PLC had a negative net margin of 126.93% and a positive return on equity of 37.58%. Endo International PLC’s revenue was down 4.9% on a year-over-year basis. During the same period last year, the firm posted $0.86 EPS. On average, equities research analysts expect that Endo International PLC will post $3.52 earnings per share for the current year.
A number of research analysts recently issued reports on the stock. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Endo International PLC in a research report on Sunday, July 23rd. Royal Bank Of Canada set a $15.00 price target on shares of Endo International PLC and gave the company a “hold” rating in a research report on Sunday, July 16th. BidaskClub raised shares of Endo International PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, July 19th. Zacks Investment Research cut shares of Endo International PLC from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Finally, Deutsche Bank AG lowered their price target on shares of Endo International PLC from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, July 7th. Three equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $12.64.
Endo International PLC Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Stock Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related stocks with our FREE daily email newsletter.